Treating Type 2 Diabetes: Looking Ahead

Updated recommendations to managing type 2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists and preventing cardiovascular events.

EP. 1: Geographic Disparities in T2DM and CVD Prevention

December 21st 2021

A call to action for more focus on the management of the type 2 diabetes epidemic around the globe.

EP. 2: Blood Pressure Management and CVD Prevention in T2DM

December 21st 2021

Updated guideline recommendations regarding the monitoring and management of patients’ blood pressure levels to reduce the risk of cardiovascular events.

EP. 3: Cholesterol-Lowering Therapies for CVD Prevention in T2DM

January 4th 2022

Considerations that factor into decisions for reducing LDL levels in patients with diabetes with statin therapy or options, such as PCSK9 inhibitors and ezetimibe.

EP. 4: Statin Therapies and Treatment-Related Myalgias

January 4th 2022

How to best prevent and manage statin-associated myalgias when managing cholesterol levels in patients with type 2 diabetes at risk for cardiovascular events.

EP. 5: Updated Guidance Regarding Aspirin Use and CVD Prevention

January 11th 2022

Guidance on the use of aspirin therapy in patients at risk of cardiovascular events, based on recently updated guideline recommendations.

EP. 6: Revised ADA Guideline Recommendations for the Treatment of T2DM

January 11th 2022

Takeaways of the most recent ADA guidelines in terms of treating patients with diabetes with metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.

EP. 7: Benefits of New Therapies Used to Treat T2DM

January 18th 2022

The benefits of using new therapies, such as SGLT2 inhibitors and GLP-1 receptor agonists, to treat type 2 diabetes.

EP. 8: Continuous Glucose Monitoring Systems for T2DM

January 18th 2022

A discussion on using continuous glucose monitoring systems to improve the management of type 2 diabetes.